IDEXX Laboratories (IDXX): Gangbangcheon B+ × Geochajesi 8/20 — Veterinary Diagnostics 45% Share Triple Moat, 85% Recurring Revenue, Watch-and-Wait at $543 Support
~45% veterinary diagnostics share + triple moat (switching costs, brand, scale) + FCF 25%, ROIC 45.8%, 85% recurring revenue — Gangbangcheon Steps 1–4 pass at Grade A. However, K-PER ~33x multiple dependency, antitrust risk, and downtrend below 50-day MA yield Gangbangcheon B+ × Geochajesi 8/20 watch-and-wait. Entry triggers: $543 support with volume or $596 50-day MA recapture + MACD golden cross.
Core Position
Veterinary diagnostics market leader at ~45% share + triple moat (switching costs, brand, scale) + FCF 25% & ROIC 45.8% capital efficiency — rated "watch-and-wait / add to watchlist" at Gangbangcheon B+ × Geochajesi 8/20. Multiple-dependent valuation (K-PER 33x operating income) is the critical swing factor
Investment Thesis
IDEXX Laboratories (IDXX) is rated "watch-and-wait — add to watchlist" at Gangbangcheon B+ × Geochajesi 8/20. Steps 1–4 pass strongly: pet humanization + TAM growing 5%+ annually (Step 1), ~45% veterinary diagnostics share as de facto standard with pricing power (Step 2), razor-and-blade recurring revenue 85% + inVue Dx flywheel (Step 3), FCF 25% + ROIC 45.8% + operating margin 31.6% Quadrant 1 growth (Step 4). Step 5 K-PER upside technically passes at base +21% / conservative +15%, but the current market multiple (~33x operating income) assumes premium multiple maintenance, capping the grade at B+. Chart is below both 50-day and 200-day MAs in a downtrend with Geochajesi 8/20 — no immediate entry. Entry triggers: ① $520–$543 support zone confirmed with volume, or ② $596–$600 (50-day MA) recovery + MACD golden cross.
① Non-Financial — Triple Moat + 85% Recurring Revenue vs. CAG Concentration & Antitrust Risk
The core strength is a triple moat. Switching costs: veterinary clinics are fully locked in through equipment installation + consumable dependency + long-term contracts (auto-renewal, volume requirements, exit penalties). Brand: 40 years of single-minded focus on animal diagnostics has established 'diagnostics = IDEXX' as the de facto standard, realizing ~4% annual net price increases. Scale: marginal cost advantage per diagnostic test from the global Reference Lab network. Add to this 85% recurring revenue (consumables + lab + subscriptions) for best-in-class earnings visibility. However, 91.8% CAG revenue concentration creates a single-business dependency — limited defense if pet diagnostic demand slows. More critically, the core of the moat — the lock-in contract structure — is a perpetual antitrust target (2022 private lawsuit, 2025 $80M payment). → Full 5-layer, moat, and competitive environment details in the Non-Financial tab.
② Validator — Gangbangcheon B+ × Geochajesi 8/20 = Excellent Asset, Multiple is the Variable
Gangbangcheon 5 steps: Steps 1–4 pass strongly at Grade A quality; Step 5 K-PER upside is numerically positive at base +21% / conservative +15%, but the current market multiple (~33x) requires premium multiple maintenance → Grade B+. Applying K-PER 30x: base target ~$684 (+21%), conservative ~$647 (+15%), optimistic ~$722 (+28%). Multiple sensitivity: a derating to 25x on growth slowdown would turn the conservative scenario negative — upside requires both earnings growth AND multiple maintenance simultaneously. Geochajesi 8/20 — Volume 2, Chart 1, Catalyst 3, Market 2. B+ × 8pts = timing gate not cleared. → Full Gangbangcheon steps, 3 K-PER scenarios, and Geochajesi details in the Validator tab.
③ Technical — Below 50-day & 200-day in Downtrend, $520–543 Support or $596 50-day Recapture as Buy Triggers
The stock has pulled back from the January 2026 high of $688 to ~$563 in June 2026. Both the 50-day MA (~$596) and 200-day MA (~$615) are above price and maintaining downward slopes — trend reversal unconfirmed. RSI ~45 recovering to neutral but pre-confirmation of a genuine reversal. Key support: $543 (primary), $520–$504 (secondary). Key resistance: $596 (50-day MA), $633 (near prior high area), $688 (52-week high). Buy signals: ① $520–$543 support defended with volume confirmation (potential double-bottom), or ② 50-day MA ($596) closing break followed by MACD golden cross confirmation. → Full 3 scenarios, RSI, and MA detail in the Technical tab.
Key Metrics
Price (Analysis Date)
~$563
2026-06-10 기준
Market Cap
~$44.7B
발행주식 ~79.4M
FCF Margin (2025)
24.6%
ROIC 45.8% (2024)
Geochajesi
8 / 20
강방천 B+·관망
K-PER Base Target
~$684
+21.5% 업사이드
Recurring Revenue Share
~85%
소모품·랩·구독
Bull Case
- Triple moat + 85% recurring revenue + pricing power — ~45% veterinary diagnostics share plus a triple moat: switching costs (long-term lock-in contracts), brand (de facto standard), and scale (global lab network). ~4% annual net price increases in practice. Consumables recurring revenue grew +17% (2025). 85% recurring revenue baseline yields best-in-class earnings predictability.
- Visit decoupling + razor-and-blade flywheel — Even when clinical visit counts decline, revenue per visit rises as diagnostic utilization (tests ordered per visit, test complexity) increases. inVue Dx (1,700+ quarterly placements) expands the installed base, while consumables and lab recurring revenue compound on top.
- Accelerating international growth + structural TAM expansion — International CAG diagnostic recurring revenue +18% (2025, above US +8%). Global pet humanization and rising veterinary infrastructure investment in emerging markets expand TAM at 5%+ annually. inVue Dx, Cancer Dx, and new Catalyst panels expand the diagnostic test category.
- IDEXX inVue Dx / Cancer Dx pipeline + Q1 2026 guidance raise — Q1 2026 earnings beat + full-year 2026 guidance raised (adjusted EPS range lifted). inVue Dx momentum and Cancer Dx launch timing provide medium-term revenue visibility. Prior antitrust risk has been at least partially priced in, providing downside buffer.
- FCF 25%, ROIC 45.8% + cumulative $2.7B buyback (2020–2024) — Outstanding capital efficiency and consistent shareholder return track record. Instead of dividends, focus on buybacks has reduced share count ~2.7% per year. Long-term value creation demonstrated over multiple cycles.
Bear Case
- Multiple-dependent valuation — derating risk on low-single-digit growth — P/E (TTM) ~41–51x depending on timing, K-PER ~33x vs. healthcare sector average ~25x (100%+ premium). If growth settles into the high-single-digit range, a 30x→25x derating scenario would turn the conservative upside negative. Upside realization depends on both earnings growth AND multiple maintenance simultaneously.
- Antitrust regulation — the moat paradox — In 2022, a private antitrust lawsuit challenged IDEXX's long-term exclusivity contracts (auto-renewal, exit penalties). ~$80M litigation-related payment occurred in April 2025. The structural tension: the same lock-in contract mechanism that creates the moat is the perpetual regulatory target — 45% share + closed ecosystem is the natural subject of antitrust scrutiny.
- 91.8% CAG concentration + veterinary demand slowdown risk — Effectively a single-business company. US clinical visits contributed -2.0% in 2025 (offset by visit decoupling, but). If decoupling hits its limit or pet adoption declines, limited defense at the consolidated level. Risk of discretionary pet healthcare spending cuts during economic downturns.
- Mars (Antech/Heska/VCA) bundle + Zoetis price assault — equal capital competition — Mars, a private company with comparable capital, bundles diagnostics + hospital + pet food vertically (acquired Heska for $1.3B in 2023). Zoetis (Vetscan, OptiCell AI blood analysis) pushing low-price POC penetration. The 45%+ share + closed ecosystem is not immune to competitive pressure.
- FX risk + chart downtrend — significant international revenue exposure means USD strength creates translation headwinds (beta ~1.66). Currently below both 50-day and 200-day MAs in a downtrend requiring sequential resistance breaks. Geochajesi Chart category score of 1 — R:R unfavorable for immediate entry.
Technical Summary
Below both the 50-day MA (~$596) and 200-day MA (~$615), both MAs maintaining downward slopes. Stock dropped -18% from the 52-week high of $688 in January 2026 to ~$563 in June 2026, now consolidating in the $543–$563 range. RSI ~45 recovering to neutral but no confirmed upside trend. Key support: $543, $520; key resistance: $596 (50-day MA), $633.
IDXX Monthly Close, 200-day MA, Support/Resistance, RSI Panel (Jun 2025–Jun 2026)
Support
S1: $543 (단기 지지·소폭 반등 확인 지점), S2: $520~504 (52주 저점 $504 + 심리선 $520 컨플루언스)
Resistance
R1: $596~600 (50일 이동평균선 · MACD 골든크로스 확인 필요 저항), R2: $633 (전고점 근방 · 주요 매물대), R3: $688 (2026년 1월 52주 고점)
Trend Analysis
Long-term (200-day MA ~$615, declining): bearish trend in progress. Medium-term (50-day MA ~$596, declining): price below 50-day MA — bearish alignment. Short-term: $543–$563 box consolidation. MA alignment: 200 > 50 > price — bearish order (full bearish alignment confirmed when 20-day MA also declines). Underperforming vs. market and sector YTD Jan–Jun 2026.
Momentum & Indicators
RSI ~45 — recovering toward neutral (from ~38 low in April 2026). MACD in negative territory, histogram maintaining weak negative. ~90%+ institutional ownership (Vanguard ~7.5%, BlackRock, State Street — passive-heavy) structurally limits selling pressure. Post-Q1 2026 earnings beat price reaction was muted (positive catalyst-price divergence) — no confirmed accumulation signal.
Key Technical Points
Both the 50-day MA (~$596) and 200-day MA (~$615) are above price and maintaining downward slopes. The critical signal is that even a strong Q1 2026 earnings beat with raised guidance produced no meaningful price response. This "positive catalyst — price divergence" suggests selling pressure currently outweighs accumulation energy. Minimum requirement to unwind bearish alignment is 50-day MA recapture with above-average volume.
The $543–$563 range is forming short-term support. If $543 holds, the structure from the January high ($688) into the current pullback offers a potential double-bottom setup. Conditions for double-bottom: support held + RSI oversold confirmation. Conversely, if $543 breaks, the next major support zone is $520–$504 (52-week low at $504).
RSI passed through near-oversold territory (~38) around April 2026 and is now recovering to ~45. Whether it can sustain above the neutral zone (40–60) hinges on whether price can recapture the 50-day MA. A stable RSI break above 50 while holding above the 50-day MA would be a medium-term trend-reversal signal. Currently pre-confirmation — avoid chasing.
At current ~$563, applying K-PER 30x gives a conservative target of ~$647 (+15%) and base ~$684 (+21%). These targets assume a slight de-rating to 30x from the current market-implied ~33x. If growth slowdown causes a derating to 25x, the conservative scenario turns negative (below $540). Recognize that the valuation upside depends simultaneously on both earnings growth AND multiple maintenance.
Trading Scenarios
Entry
1st tranche at $543 support confirmed / 2nd at $530 further decline / 3rd in $520–$504 zone
Stop
Clean close below $504 (52-week low)
Target
Target 1 ~$596 (50-day MA, +9–14%) / Target 2 ~$684 (K-PER base, +21–35%)
Staged entry to lower average cost. Initiate 1st tranche after $543 confirmed on close with volume. Must not be time-sensitive capital. Enter with awareness of multiple derating risk; hold horizon 1–2+ years.
Entry
Volume-confirmed close above 50-day ($596–$600) → enter on pullback ($580–$590)
Stop
Re-break back below the 50-day MA on close
Target
Target 1 ~$633 (resistance, +7%) / Target 2 ~$684 (K-PER base, +16%)
Strongest entry rationale with trend reversal confirmed, but higher entry price limits upside. Appropriate for conservative investors or those who need to eliminate bearish-alignment risk.
Entry
No entry now — wait for $543 support confirmation or $596 50-day MA recapture
Stop
N/A
Target
Add to watchlist + set $543 alert
Geochajesi 8/20 — timing gate not cleared. Downtrend + positive catalyst price divergence creates unfavorable R:R for immediate entry. Waiting for Scenario 1 or 2 triggers is the current recommended stance.
Bullish Signals
50-day MA ($596–$600) closing break with above-average volume (key trend-reversal signal)
$543 support defended + RSI oversold recovery confirmed (double-bottom setup)
Q2 2026 earnings beat + additional 2026 guidance raise
inVue Dx / Cancer Dx quarterly placement record disclosed
Final antitrust lawsuit settlement or dismissal announced — regulatory overhang removed
Bearish Risks
Clean $543 close break → sub-$520 further decline scenario activated
Additional downward revision to 2026 earnings guidance
Antitrust risk re-escalation — FTC re-engagement or new private lawsuit
Geochajesi sustained decline to 6 or below
Mars (Antech) aggressive pricing + disclosed meaningful market share erosion
Editor Note
"Excellent business, multiple is the key variable." IDXX has spent 40 years building 45% market share and a triple moat in a single domain — a rare achievement. The razor-and-blade flywheel, visit decoupling, and international expansion are real. However, the current multiple (~33x K-PER) already reflects excellent business quality, so return realization depends on both earnings growth AND multiple maintenance simultaneously. The chart is below both MAs in a downtrend — immediate entry is unfavorable. Add to watchlist and wait for one of two triggers: ① $543-or-below support zone with volume confirmation, ② $596 50-day MA close recapture + MACD confirmation. Until then, keep multiple sensitivity in mind: a derating to 25x turns the conservative upside negative.
* Technical analysis is based on historical data and does not guarantee future returns. Final investment decisions are your own responsibility.
IDEXX Growth Dashboard — Revenue/EPS Trend, Segment Mix, Installed Base Growth, Visit Decoupling (2020–2026E)
IDEXX Razor-and-Blade Flywheel — New Equipment → Installed Base Expansion → Recurring Consumption → Recurring Revenue → Reinvestment
Switching Cost & Moat
Moat Strength by Type
Switching Costs
Triple lock-in: equipment installation + VetLab consumable exclusivity + long-term contracts (auto-renewal, volume requirements, exit penalties). Switching costs are very high (retraining, equipment cost, testing gaps) — clinics that install IDEXX typically stay in the ecosystem for 10+ years. 2025 consumables recurring revenue +17% and Reference Lab +11% are quantitative evidence of lock-in.
Brand
40 years of single-domain focus has established "diagnostics = IDEXX" as the B2B de facto standard. Premium price acceptance + ~4% annual net price increases consistently realized. Veterinary professionals are trained on IDEXX equipment in educational programs — brand preference is institutionally reproduced as graduates enter the market.
Economies of Scale
Global Reference Lab network achieves overwhelming marginal cost advantage per diagnostic. Replicating the same global lab infrastructure would require decades of investment and billions in CAPEX. Higher network density enables faster same-day/next-day result turnaround, deepening veterinarian preference — a positive feedback structure.
Network Effects
Diagnostic data accumulated in Reference Lab (hundreds of millions of cases) enhances AI/ML diagnostic accuracy. Vello and PIMS (veterinary practice management software) ecosystem is linked to the installed base, adding platform switching costs. Currently at a medium level — potential to develop into medium–strong as data-based competition intensifies.
Technology / IP
Multi-modality integrated diagnostic platform (chemistry, hematology, immunology, molecular, digital pathology). Active pipeline: inVue Dx (leading in digital cytomorphology and AI hematology), Cancer Dx (opening new veterinary oncology diagnostic market), new Catalyst panels (pancreatic lipase, cortisol). However, AI hematology challengers (Zoetis OptiCell) are emerging — not a permanent technical monopoly.
IDEXX's triple moat — switching costs, brand, and scale — forms the core defensive structure. Switching costs (Strong): Veterinary clinics are fully locked in via equipment installation + VetLab consumable dependency + long-term contracts (auto-renewal, volume requirements, exit penalties). Switching costs are very high (retraining, re-certification, testing gaps) — clinics that install IDEXX equipment typically keep it for 10+ years. Brand (Strong): 40 years of single-minded focus on animal diagnostics has established 'diagnostics = IDEXX' as the B2B de facto standard. Premium price acceptance + ~4% annual net price increases realized. Scale (Strong): Global Reference Lab network provides marginal cost advantage per diagnostic — a competitor would need massive CAPEX and decades to replicate the same scale. Network effects (Medium): Reference Lab + software (Vello, PIMS) data integration is building ecosystem lock-in. Technology/IP (Medium–Strong): Multi-modality integration (chemistry, hematology, immunology, molecular, digital pathology), with inVue Dx, Cancer Dx, and ongoing pipeline innovation.
Management & Governance
CEO: Jay Mazelsky — took office in 2019 (interim following predecessor Jon Ayers' accident, then formalized). Joined IDEXX in 2012; prior career at Philips Healthcare as an executive. University of Rochester (Mathematics), Chicago Booth MBA. Consistently pursued innovation-led growth strategy — new product pipeline including inVue Dx, Cancer Dx, Vello, and accelerated international expansion. Track record of consistent quarterly earnings beats and guidance raises. Internal-promotion type with deep industry expertise. CFO: Brian McKeon (2014–) retired June 2025 → succeeded by Andrew Emerson (20 years internal, from CAG finance). Orderly internal succession maintains management continuity. Board Chair: Larry Kingsley (former Pall Corp CEO). Predecessor CEO Jon Ayers' 20-year tenure growing revenue from $380M to $3B and 100x+ stock appreciation is the cultural bedrock. Capital allocation: no dividend; focus on buybacks ($2.7B cumulative 2020–2024, ~-7% shares outstanding).
Competitive Landscape
Mars (Antech / Heska / VCA)
Strongest direct competitor. Private with no financial disclosures but comparable capital. Vertically integrated bundle of diagnostics (Antech, Heska) + veterinary hospitals (VCA) + pet food directly challenges the IDEXX ecosystem. 2023 Heska ($1.3B) acquisition strengthened POC diagnostics. IDEXX–Antech is effectively a duopoly.
Zoetis (Vetscan / OptiCell)
Listed animal health leader (NASDAQ: ZTS). Vetscan chemistry analyzer pushing low-price POC penetration. OptiCell (AI-based hematology) signals competition in the digital pathology space where inVue Dx operates. Strong R&D and global sales network, but lacks Reference Lab infrastructure.
Thermo Fisher / bioMérieux
Molecular diagnostics and microbiology specialists. Indirect competition in some specialized Reference Lab testing categories. Limited dedicated veterinary focus, but the potential to transplant human diagnostic technology into animal markets is a medium-term threat.
Mindray (중국)
Low-price veterinary diagnostic equipment push in China and emerging markets. Growing in lower-price emerging market segments not yet penetrated by IDEXX. Limited direct threat in developed markets due to lack of global Reference Lab network, brand, and regulatory approvals.
Direct competition: Mars (Antech, Heska, VCA, SYNLAB Vet) is the strongest direct threat. Non-public with no financial disclosures but comparable capital — applying vertical bundle pressure through diagnostics + hospital + pet food integration. The 2023 Heska acquisition ($1.3B) bolstered its in-clinic equipment position. IDEXX–Antech is effectively a duopoly. Zoetis (Vetscan, OptiCell AI hematology): pushing low-price POC penetration with strong R&D. The AI-based hematology analysis technology (OptiCell) signals upcoming competition in the digital pathology space where inVue Dx operates. Others: Thermo Fisher, bioMérieux, Neogen (rapid food safety), Mindray (China, price competition). Differentiation: IDEXX is the only single vendor integrating equipment + consumables + Reference Lab + software in a closed ecosystem. Single-modality or POC-only competitors are numerous, but there is virtually no substitute for the integrated ecosystem. However, Mars's ongoing bundle strategy strengthening could gradually compress pricing power and market share — a long-term structural risk.
ESG & Summary
Environmental: IDEXX's core business directly advances animal welfare through veterinary diagnostic excellence. Reference Lab's large-batch processing is resource-efficient per test vs. in-clinic single-test processing. Carbon neutrality target by 2030 disclosed. Social: Products supplied in 175+ countries — contributing to improved global access to veterinary diagnostics. ~11,000 employees. Participates in "One Health" initiative (linking human, animal, and environmental health) — animal infectious disease monitoring provides indirect early warning for zoonotic disease risk. Governance: Pure US corporation (NASDAQ), no owner risk. Passive institutional-heavy ownership (Vanguard ~7.5%, BlackRock, State Street) provides independent oversight. CEO/Board Chair separation maintained. No dividend; focused buybacks + high quarterly earnings disclosure transparency. However, the antitrust lawsuit (2022–) and 2025 ~$80M payment are notable governance risk items requiring disclosure.
Key Risks
Multiple Derating — Premium Justification Weakens if Growth Settles into High Single Digits
Current P/E (TTM) ~41–51x, PEG ~3.3, EV/EBITDA ~34x — 100%+ premium vs. healthcare sector average. Implied K-PER ~33x. If growth settles into high-single-digit (~8%), a derating to 25x would push the conservative target below the current price. The core risk: upside realization requires both earnings growth AND multiple maintenance simultaneously.
Antitrust Regulation — The Paradoxical Vulnerability Within the Moat Structure
Precedent: the FTC intervened in IDEXX's distribution exclusivity contracts in 2013. In 2022, a private antitrust lawsuit targeted IDEXX's long-term exclusivity contracts (auto-renewal, volume requirements, exit penalties). ~$80M litigation-related payment occurred in April 2025. The lock-in contract structure at the core of the moat can become the direct target of regulatory unwinding orders in stricter enforcement environments. 45% market share + closed ecosystem is a structural antitrust surveillance target.
91.8% CAG Concentration + Veterinary Demand Slowdown Risk
Effectively a single-business company. Water (4.7%), LPD (3.1%), and Other (0.4%) segments cannot meaningfully offset a CAG downturn. US clinical visits contributed -2.0% in 2025 (offset by visit decoupling). If pet adoption rates decline, demographic shifts toward lower-cost pets reduce per-visit diagnostic revenue, and economic downturns reduce discretionary pet healthcare spending simultaneously — limited structural defense.
FX / Competition (Mars Bundle + Zoetis Price Assault) + High Beta
USD strength creates translation headwinds in a global revenue structure. Beta ~1.66 means above-average volatility vs. the market. Mars (integrated Antech+Heska bundle) price pressure and Zoetis (OptiCell AI hematology) technology competition apply persistent long-term pressure on market share and pricing power. If Mars bundle discounting against stand-alone IDEXX contracts escalates, IDEXX's price increase capacity may become constrained.
Gangbangcheon 4/5 passed
Gangbangcheon 5 steps: Steps 1–4 pass strongly at Grade A business quality; Step 5 K-PER technically passes but premium multiple assumption caps at B+. Step 1: Pet humanization + TAM 5%+ growth + animal diagnostics as structural essential ✅. Step 2: ~45% veterinary diagnostics share, de facto standard, ~4% annual price increases — Grade A ✅. Step 3: 85% recurring revenue + inVue Dx flywheel + stable internal succession ✅. Step 4: FCF 25%, ROIC 45.8%, operating margin 31.6%, Quadrant 1 growth ✅. Step 5: Conservative +15%, base +21% — numerically passes ⚠️ (assumes K-PER 33x→30x; derating risk on growth slowdown) → Grade B+. Geochajesi 8/20 = B+ × 8pts = no immediate entry.
IDEXX Profitability — Revenue & Operating Income (bar) vs ROA & ROE (line), 2021–2025 (GAAP basis, note ROE distortion)
Gangbangcheon 5-Step Checklist
Step 1
Industry / Infrastructure Tailwind ✅
TAM: Global veterinary diagnostics market growing 5%+ annually. Pet humanization structural demand — social shift treating pets as family members structurally increases diagnostic and preventive care spending. Essential-goods character: pet healthcare is economically defensive (non-discretionary medical spend). inVue Dx and Cancer Dx expand the diagnostic category itself, creating new demand. International market expansion: rising veterinary infrastructure investment in emerging markets expands long-term TAM.
Step 2
Market Position ✅ — Grade A
Approximately 45% share (2024 est.) — dominant #1 in veterinary diagnostics. Pricing power: ~4% global net price increase in 2025 (US ~3.5%) — sustained above-inflation unit price growth. B2B de facto standard: "diagnostics = IDEXX" in clinical practice. Customer diversification: no single customer over 30% concentration. Market position, pricing power, and customer diversification all Grade A.
Step 3
Business Model / Leadership ✅
Scalability: new products (inVue Dx, Cancer Dx), geographic expansion (international +18%), category expansion (digital pathology, AI diagnostics), and software subscription (Vello). 85% recurring revenue provides best-in-class revenue predictability. Leadership: professional management (no owner risk), stable internal succession (CFO McKeon→Emerson), predecessor Ayers' 20-year 100x track record as cultural bedrock. inVue Dx quarterly placement record validates execution.
Step 4
Financial Quality ✅
FCF margin 24.6% (2025), ROIC 45.8% (2024) — best-in-class capital efficiency. P×Q-C: P↑ (net price increases), Q↑ (installed base expansion), C→ (cost stable via scale) → operating margin 31.6%, Quadrant 1 confirmed. ROA ~27% stable for 5 consecutive years. Net income $1,059M (2025). ROE distorted by buybacks — ROA and operating margin are the true profitability metrics. Financial quality is best-in-class for the peer group.
Step 5
K-PER Valuation ⚠️ — Passes but Requires Multiple Maintenance
Base operating income: FY2025 $1,360M. 3-year projection period (→FY2028). Base +21%, conservative +15% upside — numerically passes the 10% threshold. However, applying K-PER 30x from the current market-implied ~33x still leaves the conservative upside at a limited +15%. A derating to 25x would flip the conservative scenario to ~$537 (-5%). Grade capped at B+ because upside requires simultaneous earnings growth AND multiple maintenance.
K-PER Scenario Analysis (3-Year Target)
Base operating income: FY2025 $1,360M. Projection period: 3 years (FY2025→FY2028). K-PER 30x applied — slight de-rating from current market-implied ~33x, below the historical median operating income multiple for IDEXX. Per-share conversion based on ~79.4M shares (est.). Upside drivers: earnings growth (8–12%) + multiple maintenance (30x). Sensitivity: a derating to 25x flips the conservative target to ~$537 (-5%).
| Scenario | Annual Growth | Non-GAAP Profit | Applied PER | Target Cap | Upside |
|---|---|---|---|---|---|
| Conservative (8% Op. Income Growth) | 연 8% 영업이익 성장 | FY2028 영업이익 $1,713M | 30x | ~$647 (~$51.4B) | +15% |
| Base (10% Op. Income Growth) | 연 10% 영업이익 성장 | FY2028 영업이익 $1,810M | 30x | ~$684 (~$54.3B) | +21% |
| Optimistic (12% Op. Income Growth) | 연 12% 영업이익 성장 | FY2028 영업이익 $1,911M | 30x | ~$722 (~$57.3B) | +28% |
Geochajesi Score (8/20)
~90%+ institutional ownership (Vanguard ~7.5%, BlackRock, State Street — passive-heavy) structurally limits selling pressure (+1). Large-cap baseline liquidity and average daily volume met (+1). However, active new accumulation signal unclear — muted price response to Q1 earnings beat (positive catalyst divergence). 13F real-time data not available, limiting accumulation signal verification.
Below both 50-day and 200-day MAs in a downtrend → bearish alignment immediately caps at maximum 1 point (+1). $543–$563 support zone holding (oversold recovery potential). RSI ~45 recovering toward neutral but bullish trend reversal unconfirmed. MACD remaining negative. No additional score without 50-day MA ($596) break + MACD golden cross.
Q1 2026 earnings beat + 2026 guidance raised (+1) — solid earnings momentum. inVue Dx quarterly placement record 1,700+ + Cancer Dx pipeline (+1) — medium-term growth visibility. International recurring revenue accelerating +18% (+1) — international growth story confirmed. However, antitrust lawsuit + $80M payment uncertainty offsets catalyst. Chart analysis: muted price response to positive catalysts — cannot apply full score.
Animal diagnostics sector is economically defensive (non-discretionary healthcare) (+1). Healthcare / pet theme provides structural support (+1). However, diagnostics/healthcare is not the leading theme — capital flows disfavor vs. market-leading sectors in 2026 (AI, semiconductors). Real-time sector rotation and daily index data unavailable — conservative scoring under neutral market assumption.
Entry Strategy (3 Tranches)
Geochajesi 8/20 + below 50-day MA in downtrend makes immediate entry unfavorable R:R. Add to watchlist and wait for one of the two triggers below. Time-sensitive capital absolutely prohibited.
$543 confirmed on close with volume → initiate 1st tranche. 3-tranche target avg cost ~$527. Stop on clean break below $504 (52-week low). K-PER base target ~$684 (+30%), R:R ~3.0:1. Minimum 1–2 year hold. Multiple maintenance risk must be understood.
Strongest entry rationale — trend reversal confirmed. Higher entry price limits upside to K-PER base target to ~+16%. Stop on re-break below 50-day MA. Appropriate for conservative investors who require trend reversal confirmation.
Exit Triggers
K-PER base target ~$684 (+21%) reached → take profit on 1/3–1/2; hold remainder pending momentum and multiple check
K-PER optimistic target ~$722 (+28%) reached → full exit on remaining shares; consider early liquidation if multiple looks overheated
Antitrust escalation — FTC re-engagement, lock-in contract unwind order, or new lawsuit escalation → immediate full position reassessment
Gangbangcheon Steps 1–4 downgrade signals — meaningful market share loss, pricing power breakdown (net price increases ≤0%), FCF margin sustained below 20%
Geochajesi sustained decline to 6 or below, or K-PER conservative upside turns negative (25x derating materializes)
Portfolio Weight Recommendation
Immediate lump-sum entry deferred. 3–5% total weight on staged entry at $543 or below support zone. Long-term conviction investors may target 5–7% at price levels where conservative K-PER upside improves to 20%+ ($504–$520). Time-sensitive or short-horizon capital absolutely prohibited.
Editor Note
"The 40-year moat paradox — the multiple is everything." IDXX has built a triple moat and 85% recurring revenue over 40 years of single-domain focus — a rare achievement. FCF 25%, ROIC 45.8%, 4% annual price increases — these are real. But this excellent business is already priced into a K-PER of ~33x, so investment returns depend on simultaneously achieving earnings growth (10%) AND multiple maintenance (30x+). If growth slows into high-single digits, a 25x derating would flip the conservative upside negative. The chart is in a downtrend — unfavorable for immediate entry. Add to watchlist and set a $543 alert. When that zone arrives, real safety margin opens up.
Financial Data
Fiscal year: calendar year (Jan–Dec). FY2025 = January–December 2025 (completed and reported). Currently in FY2026 Q2 (April–June 2026). K-PER projection period: 3 years out = FY2028 (ending December 2028). Financial figures in USD millions ($M). FY2021 operating income/net income and annual ROE figures are estimates — FY2025 10-K basis with some estimated items.
| Period | Revenue | Growth | Op. Income | Op. Margin |
|---|---|---|---|---|
| FY2023Consecutive growth + operating margin breaching 30%. ROA 27.8% (best-in-class). FCF margin 21.0%. US clinical visit recovery + accelerating international CAG recurring revenue growth. inVue Dx early placements expanding installed base +11%. | $3,661M | +8.7% YoY | $1,097M | 30.0% |
| FY2024Operating margin 28.9% (short-term moderation). FCF margin 20.7%. ROIC 45.8% (best-in-class). Cumulative $2.7B buybacks (2020–2024). US clinical visit weakness (~-1.5% contribution) offset by visit decoupling. Consumables recurring revenue continued growth. | $3,898M | +6.5% YoY | $1,128M | 28.9% |
| FY2025Record revenue and operating income. Operating margin 31.6%, highest in 5 years. FCF margin 24.6%, net income $1,059M. International CAG recurring revenue +18% (above US +8%). inVue Dx quarterly placement record of 1,700+. Q1 2026 earnings beat + full-year 2026 guidance raised (adjusted EPS guidance range lifted). | $4,304M | +10.4% YoY | $1,360M | 31.6% |
GAAP vs Non-GAAP Note
IDEXX applies US GAAP and files 10-K (annual) and 10-Q (quarterly) with the SEC as a NASDAQ-listed US corporation. Reported GAAP vs. adjusted (Non-GAAP) earnings differ primarily due to stock-based compensation and acquisition-related intangible amortization. ROE is significantly distorted by equity shrinkage from cumulative buybacks — profitability must be assessed via operating margin and ROA. Operating income and growth rates used in K-PER calculations are assumptions that may differ from actual results. FY2021 operating income, net income, and annual ROE figures are estimates derived from public data.
Key Valuation Metrics
K-PER Base Target Price (FY2028)
~$684 (+21%)
Base operating income growth 10%/yr → FY2028 operating income $1,810M × K-PER 30x = $54.3B market cap → ~$684/share (~79.4M shares). Slight de-rate from the current market-implied ~33x. Aligns with analyst consensus target range (~$650–$700).
K-PER Conservative Target Price (FY2028)
~$647 (+15%)
Conservative operating income growth 8%/yr → FY2028 $1,713M × K-PER 30x = $51.4B → ~$647/share. +15% upside. Above the 10% safety margin threshold, but a derating to 25x would turn it to ~$537 (-5%). Maintaining a 30x multiple is the critical assumption.
Operating Margin / FCF Margin (2025)
31.6% / 24.6%
Operating margin 31.6% is the 5-year high, confirming Quadrant 1 (revenue↑ + margin↑) growth. FCF margin 24.6% is best-in-class. Free cash flow is prioritized for buybacks (no dividend). 2026 operating margin guidance expected to maintain ~31–32%.
ROA / ROIC (2024/2025)
~27% / 45.8%
ROA ~27% (2025 est.) — stable ~27% maintained for 5 consecutive years. The true profitability metric. ROE distorted to 66–115% by cumulative buybacks shrinking equity (handle with care). ROIC 45.8% (2024) — overwhelming capital efficiency in peer comparison. Best-in-class excess return above cost of capital.
International Growth / Installed Base (2025)
+18% / +12%
International CAG diagnostic recurring revenue +18% (reported, 2025) — more than double the US +8% growth rate. International confirmed as the primary growth engine. Premium equipment installed base YoY +12% (accelerating from 2024's +11%) — driven by inVue Dx quarterly placements of 1,700+. Installed base expansion is a leading indicator for future consumables and lab recurring revenue.
Buyback History / Share Count Reduction
$2.7B (2020–2024)
Cumulative $2.7B buybacks 2020–2024. Share count down ~7% (2020–2024). Average buyback price ~$453 — +24% unrealized gain vs. current price ($563). EPS automatically boosted by share reduction with no dividend paid. FY2025 shares outstanding ~79.4M (est.).
* GAAP basis. All figures are estimates based on public information and are not investment advice.
Same Exchange
- GSITGSI Technology (GSIT): Gangbangcheon C × Geochajesi 12/20 — APU Computing-in-Memory Binary Option, June Drone Demo + Galloway Activism Watch-and-Wait
- PPTAPerpetua Resources (PPTA): Gangbangcheon B × Geochajesi 13/20 — US-Only Antimony + EXIM $2.9B Construction Start, P/NAV 0.54x Watch-and-Wait
- SPSCSPS Commerce (SPSC): Gangbangcheon B × Geochajesi 6/20 — Dual EDI Moat, Historic Undervaluation at -73% from Peak, Watch-and-Wait